Artelo Biosciences, Inc.

ARTL
$4.22 (-6.74%)
01:59 PM · Apr 21 · NASDAQ
#22 Solana Treasuries

Artelo Biosciences, Inc.

ARTL
#22 in Solana Treasuries
Solana Treasury Stock · NASDAQ · Solana Beach, US
$4.22 (-6.74%)
01:59 PM · Apr 21, 2026
SOL Holdings
1,525 SOL Treasury
Treasury Value
$130.91K
SOL per Share
0.0022
mNAV
68.49x
Market Cap
$8.97M
Enterprise Value
$8.78M

Market Overview

Market Cap
Shares Outstanding
50-Day Moving Average
200-Day Moving Average
Average Volume (20 Days)
Beta (5Y)
  • Chart chart view
  • Table table view
  • Price
  • Market Cap MCap
  • Shares
Start Date
start date
to
End Date
start date
Date OPEN HIGH LOW CLOSE VWAP VOLUME %CHG $CHG
1D
5D
1M
3M
6M
YTD
1Y
5Y

Artelo Biosciences, Inc. Company Overview

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Artelo Biosciences, Inc. website url Visit Website Artelo Biosciences, Inc. linkedin url Artelo Biosciences, Inc. twitter url
Stock Exchange NASDAQ
IPO Date 2019-06-21
Number of Employees 6
Headquarters Solana Beach, CA, US

Key Executives

Dr. Andrew Yates Ph.D.

Senior Vice President & Chief Scientific Officer
Dr. Andrew Yates Ph.D. linkedin Dr. Andrew Yates Ph.D. twitter

Dr. Steven D. Reich M.D.

Chief Medical Officer
Dr. Steven D. Reich M.D. linkedin Dr. Steven D. Reich M.D. twitter

Mr. Jason H. Baybutt

Senior Vice President of Finance
Mr. Jason H. Baybutt linkedin Mr. Jason H. Baybutt twitter

Mr. Gregory D. Gorgas M.B.A.

President, Chief Executive Officer, Secretary & Director
Mr. Gregory D. Gorgas M.B.A. linkedin Mr. Gregory D. Gorgas M.B.A. twitter

Featured Posts

View all articles

Press Releases

No press releases found.

SEC Filings

Form Type Filed Accepted Source

ARTL Frequently Asked Questions

The next earnings report date for Artelo Biosciences, Inc. (ARTL) is scheduled for May 19, 2026. Stay up to date with ’s financial results and key announcements by visiting our Earnings Tracker or by subscribing to earnings alerts. Here we also provide ARTL earnings call summaries and transcripts.

As of September 30, 2025, Artelo Biosciences, Inc. holds approximately 1,524.69 SOL . For more comprehensive insights, you can track ARTL 's Solana holdings on our Solana Treasuries page.

The current stock price of Artelo Biosciences, Inc. (ARTL) is $4.22 as of 01:59 PM 21/04/26. For live stock updates and company rankings, view our Bitcoin mining stocks by market cap table.

The latest news for Artelo Biosciences, Inc. (ARTL) includes Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile published on April 20, 2026. For more details and ongoing updates, visit the ARTL news section.